HomeAbout

TL;DR CNBC


Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma - TL;DR CNBC

Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma

Publishing timestamp: 2023-12-20 07:00:01


Summary

Drugmakers are ending the year with historic firsts that will shape the pharmaceutical industry in the future. COVID vaccines and treatments saw a decline in demand, while attention shifted to weight loss medications and new Alzheimer's drugs. The weight loss drug market has become a gold rush, with Novo Nordisk and Eli Lilly leading the way. The approval of the first-ever Alzheimer's treatment and the rollout of vaccines against respiratory syncytial virus were significant milestones. However, the COVID product market saw a steep drop in demand as the world emerged from the pandemic. The pharmaceutical industry also faced challenges with the new Medicare drug price negotiations.


Sentiment: MIXED

Tickers: 4523.T-JPJNJPFEBMYMRKAZN-GBLLYAMGNNOVO.B-DKBIIB

Keywords: biogen incpfizer incunited statesbiotech and pharmaceuticalsnovo nordisk a/samgen incbusiness newsbusinesseisai co ltdpharmaceuticalshealth care industryeli lilly and cobiotechnology

Source: https://www.cnbc.com/2023/12/20/weight-loss-drugs-covid-downturn-pharma-had-a-year-full-of-firsts.html


Developed by Leo Phan